Imatinib Mesylate Exerts Anti-Proliferative Effects on Osteosarcoma Cells and Inhibits the Tumour Growth in Immunocompetent Murine Models

Osteosarcoma is the most common primary malignant bone tumour characterized by osteoid production and/or osteolytic lesions of bone. A lack of response to chemotherapeutic treatments shows the importance of exploring new therapeutic methods. Imatinib mesylate (Gleevec, Novartis Pharma), a tyrosine kinase inhibitor, was originally developed for the treatment of chronic myeloid leukemia. Several studies revealed that imatinib mesylate inhibits osteoclast differentiation through the M-CSFR pathway and activates osteoblast differentiation through PDGFR pathway, two key cells involved in the vicious cycle controlling the tumour development. The present study investigated the in vitro effects of imatinib mesylate on the proliferation, apoptosis, cell cycle, and migration ability of five osteosarcoma cell lines (human: MG-63, HOS; rat: OSRGA; mice: MOS-J, POS-1). Imatinib mesylate was also assessed as a curative and preventive treatment in two syngenic osteosarcoma models: MOS-J (mixed osteoblastic/osteolytic osteosarcoma) and POS-1 (undifferentiated osteosarcoma). Imatinib mesylate exhibited a dose-dependent anti-proliferative effect in all cell lines studied. The drug induced a G0/G1 cell cycle arrest in most cell lines, except for POS-1 and HOS cells that were blocked in the S phase. In addition, imatinib mesylate induced cell death and strongly inhibited osteosarcoma cell migration. In the MOS-J osteosarcoma model, oral administration of imatinib mesylate significantly inhibited the tumour development in both preventive and curative approaches. A phospho-receptor tyrosine kinase array kit revealed that PDGFRα, among 7 other receptors (PDFGFRβ, Axl, RYK, EGFR, EphA2 and 10, IGF1R), appears as one of the main molecular targets for imatinib mesylate. In the light of the present study and the literature, it would be particularly interesting to revisit therapeutic evaluation of imatinib mesylate in osteosarcoma according to the tyrosine-kinase receptor status of patients.

[1]  K. Antman,et al.  Imatinib mesylate--a new oral targeted therapy. , 2002, The New England journal of medicine.

[2]  L. Shultz,et al.  Establishment and characterization of a new osteogenic cell line (MOS-J) from a spontaneous C57BL/6J mouse osteosarcoma. , 2002, In vivo.

[3]  P. Lollini,et al.  NVP-BEZ235 as a New Therapeutic Option for Sarcomas , 2010, Clinical Cancer Research.

[4]  Randall T. Moon,et al.  Proximal events in Wnt signal transduction , 2009, Nature Reviews Molecular Cell Biology.

[5]  L. Jia,et al.  Knockdown of AXL Receptor Tyrosine Kinase in Osteosarcoma Cells Leads to Decreased Proliferation and Increased Apoptosis , 2013, International journal of immunopathology and pharmacology.

[6]  Tomoyuki Saito,et al.  Inhibition of lung metastasis of osteosarcoma cell line POS-1 transplanted into mice by thigh ligation. , 2002, Cancer letters.

[7]  J. Blay,et al.  Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  G. Rosen,et al.  Chemotherapy, en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma , 1976, Cancer.

[9]  Gerhard Dürnberger,et al.  Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. , 2007, Blood.

[10]  Dong Ho Kim,et al.  Epidermal Growth Factor Receptor: Is It a Feasible Target for the Treatment of Osteosarcoma? , 2012, Cancer research and treatment : official journal of Korean Cancer Association.

[11]  C. Antonescu,et al.  Platelet‐derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma , 2008, Cancer.

[12]  P. Layrolle,et al.  Adhesion and osteogenic differentiation of human mesenchymal stem cells on titanium nanopores. , 2011, European cells & materials.

[13]  Anne-Marie Cleton-Jansen,et al.  IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma , 2013, BMC Cancer.

[14]  E. Kleinerman,et al.  Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell lines , 2012, Oncogenesis.

[15]  Daisuke Kitagawa,et al.  Activity‐based kinase profiling of approved tyrosine kinase inhibitors , 2013, Genes to cells : devoted to molecular & cellular mechanisms.

[16]  D. Heymann,et al.  Mechanisms of bone repair and regeneration. , 2009, Trends in molecular medicine.

[17]  A. Petrilli,et al.  C-kit expression in human osteosarcoma and in vitro assays. , 2011, International journal of clinical and experimental pathology.

[18]  N. Sevenet,et al.  Imatinib mesylate (Gleevec) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity. , 2006, European journal of pharmacology.

[19]  B. Pitard,et al.  Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. , 2007, Cancer research.

[20]  D. Heymann,et al.  Bone sarcomas: pathogenesis and new therapeutic approaches , 2011 .

[21]  M. Heymann,et al.  Current Therapeutic Strategies and Novel Approaches in Osteosarcoma , 2013, Cancers.

[22]  S. Stacker,et al.  Importance of Wnt signaling in the tumor stroma microenvironment. , 2008, Current cancer drug targets.

[23]  X. Zi,et al.  The Wnt signaling pathway: implications for therapy in osteosarcoma , 2011, Expert review of anticancer therapy.

[24]  C. Supuran,et al.  The protein tyrosine kinase inhibitors imatinib and nilotinib strongly inhibit several mammalian alpha-carbonic anhydrase isoforms. , 2009, Bioorganic & medicinal chemistry letters.

[25]  A. Freywald,et al.  Dancing with the dead: Eph receptors and their kinase-null partners. , 2011, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[26]  A. Fedenko,et al.  A Meta-Analysis of Osteosarcoma Outcomes in the Modern Medical Era , 2012, Sarcoma.

[27]  R. Gorlick,et al.  Inhibition of Src Phosphorylation Alters Metastatic Potential of Osteosarcoma In vitro but not In vivo , 2009, Clinical Cancer Research.

[28]  B. Klein,et al.  Studies of bone and soft‐tissue tumours induced in rats with radioactive cerium chloride , 1977, International journal of cancer.

[29]  P. Hogendoorn,et al.  Concise Review: Mesenchymal Tumors: When Stem Cells Go Mad , 2011, Stem cells.

[30]  G. Moriceau,et al.  Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process. , 2010, Cancer research.

[31]  J. Cornish,et al.  Imatinib Promotes Osteoblast Differentiation by Inhibiting PDGFR Signaling and Inhibits Osteoclastogenesis by Both Direct and Stromal Cell‐Dependent Mechanisms , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[32]  O. Delattre,et al.  Mesenchymal stem cell features of Ewing tumors. , 2007, Cancer cell.

[33]  Jingnan Shen,et al.  Gas6/Axl mediates tumor cell apoptosis, migration and invasion and predicts the clinical outcome of osteosarcoma patients. , 2013, Biochemical and biophysical research communications.

[34]  G. Ehninger,et al.  Inhibition of platelet‐derived growth factor receptorβ by imatinib mesylate suppresses proliferation and alters differentiation of human mesenchymal stem cells in vitro , 2007, Cell proliferation.

[35]  Francisco Cervantes,et al.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.

[36]  K. Vandyke,et al.  Dysregulation of bone remodeling by imatinib mesylate. , 2010, Blood.

[37]  S R Piersma,et al.  Surface proteomic analysis of osteosarcoma identifies EPHA2 as receptor for targeted drug delivery , 2013, British Journal of Cancer.

[38]  Raphaela Fritsche-Guenther,et al.  De novo expression of EphA2 in osteosarcoma modulates activation of the mitogenic signalling pathway , 2010, Histopathology.

[39]  G. Moriceau,et al.  Synergistic inhibitory effect of apomine and lovastatin on osteosarcoma cell growth , 2012, Cancer.

[40]  J. Yokota,et al.  Biological properties and gene expression associated with metastatic potential of human osteosarcoma , 2004, Clinical & Experimental Metastasis.

[41]  K. Matsuo,et al.  Bone cell interactions through Eph/ephrin , 2012, Cell adhesion & migration.

[42]  P. Adamson,et al.  A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A Children's Oncology Group study , 2008, Pediatric blood & cancer.